eFFECTOR Therapeutics (EFTR) Projected to Post Quarterly Earnings on Tuesday

eFFECTOR Therapeutics (NASDAQ:EFTR) is expected to issue its quarterly earnings data on Tuesday, January 21st. Analysts expect the company to announce earnings of ($2.02) per share for the quarter.

eFFECTOR Therapeutics Price Performance

Shares of eFFECTOR Therapeutics stock opened at $0.00 on Monday. The firm has a market cap of $940.00, a P/E ratio of 0.00 and a beta of 0.56. eFFECTOR Therapeutics has a 12 month low of $0.00 and a 12 month high of $17.75.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.